In summary, co-expression of NRP2 and NCAM1 is confined to very early osteogenic precursor cells and increases upon osteogenic and fibrogenic differentiation, rendering previously clinically approved NRP2 modulators [43] which is a promising therapeutic modality to target fibrosis and osteosclerosis in MPN, MDS and MPN/MDS overlap syndromes. This evidence concerns the gene NCAM1 and myeloproliferative disorder.